Results 31 to 40 of about 119,088 (108)
Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors
Cancer Medicine, Volume 11, Issue 2, Page 340-347, January 2022., 2022 This combination therapy with ADI‐PEG 20 and Doxil had a reversible and manageable toxicity profile, and patients tolerated the treatment. Tumor shrinkage and prolonged duration of therapy were observed in several patients. Abstract Background Arginine depletion interferes with pyrimidine metabolism and DNA damage repair pathways.
Shuyang Yao +10 more
wiley +1 more source
The Landscape of Cancer Metabolism as a Therapeutic Target. [PDF]
Pathol IntABSTRACT Cancer cells reprogram their metabolism during progression to adapt to the tumor microenvironment, which is characterized by distinct differences in nutrient availability, oxygen concentrations, and acidity. This metabolic reprogramming can simultaneously create metabolic vulnerabilities unique to cancer cells, making cancer metabolism a ...
Ohshima K.
europepmc +2 more sources
Metabolic regulation in the immune response to cancer
Cancer Communications, Volume 41, Issue 8, Page 661-694, August 2021., 2021 In this review, we describe the molecular mechanisms through which systemic, microenvironmental and microbial metabolites potentially influence the host immune response to mediate malignant progression and therapeutic intervention. We summarize the primary interplaying factors that constitute metabolism, immunological reactions and cancer with a focus ...
Qi Wu +4 more
wiley +1 more source
The Journal of Clinical Investigation, 2022 New approaches for the management of glioblastoma (GBM) are an urgent and unmet clinical need. Here, we illustrate that the efficacy of radiotherapy for GBM is strikingly potentiated by concomitant therapy with the arginine-depleting agent ADI-PEG20 in a
Nabil Hajji +18 more
doaj +1 more source
BMC Cancer, 2018 In the original publication of this article [1], published on 8 February 2018, it was noticed that the acknowledgement of the source of the drug ADI-PEG20 was missing.
Lina Mörén +6 more
doaj +1 more source
, 2020 ADI-PEG20 efficacy in an extended panel of ovarian cancer cell lines. Cells were treated with 0.63 µg/mL ADI-PEG20. First row represents ASS1 expressing cell lines, whereas the rest of the cells are ASS1 deficient, therefore sensitive to ADI-PEG20 ...
Dawn R. Cochrane (14917856) +23 more
core +1 more source
Cell Reports, 2016 Argininosuccinate synthase 1 (ASS1) is the rate-limiting enzyme for arginine biosynthesis. ASS1 expression is lost in a range of tumor types, including 50% of malignant pleural mesotheliomas.
Matthew Locke +10 more
doaj +1 more source
Cellular Physiology and Biochemistry, 2018 Arginine auxotrophy occurs in certain tumor types and is usually caused by the silencing of argininosuccinate synthetase 1 or arginine lyase genes. Such tumors are often associated with an intrinsic chemoresistance and thus a poor prognosis.
Christin Riess +6 more
doaj +1 more source
Pegylated Arginine Deiminase Depletes Plasma Arginine but Maintains Tissue Arginine Availability in Young Pigs [PDF]
, 2021 Pegylated arginine deiminase (ADI-PEG20) results in the depletion of arginine with the production of isomolar amounts of citrulline. This citrulline has the potential to be utilized by the citrulline recycling pathway regenerating arginine and sustaining
Nguyen, Trung C +9 more
core +1 more source
Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM
BMC Cancer, 2018 Background Tumour cells have a high demand for arginine. However, a subset of glioblastomas has a defect in the arginine biosynthetic pathway due to epigenetic silencing of the rate limiting enzyme argininosuccinate synthetase (ASS1).
Lina Mörén +6 more
doaj +1 more source